NASDAQ : CRIS
Curis, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.6 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.46M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.46M |
| Enterprise Value | -1.57M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 4.10M |
| Shares Outstanding | 4.10M |
| Shares Change (YoY) | +348.43% |
| Shares Change (QoQ) | +101.31% |
| Owned by Insiders (%) | 2.14% |
| Owned by Institutions (%) | 17.15% |
| Float | 4.02M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.57 |
| Forward PS | 0.27 |
| PB Ratio | 0.25 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.49 |
| Quick Ratio | 0.37 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -29.99 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -93.23% |
| Return on Invested Capital (ROIC) | -185.56% |
| Return on Capital Employed (ROCE) | -679.00% |
| Weighted Average Cost of Capital (WACC) | 41.97% |
| Revenue Per Employee | $179,750 |
| Profits Per Employee | -$881,375 |
| Employee Count | 24 |
| Asset Turnover | 0.18 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 3.10 |
| 52-Week Price Change | -98.00% |
| 50-Day Moving Average | 0.92 |
| 200-Day Moving Average | 9.04 |
| Relative Strength Index (RSI) | 42.19 |
| Average Volume (20 Days) | 631,696 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 439,270 |
| Short Previous Month | 179,462 |
| Short % of Shares Out | 10.70% |
| Short % of Float | 10.94% |
| Short Ratio (days to cover) | 2.18 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 4.31M |
| Gross Profit | -21.34M |
| Operating Income | -35.95M |
| Pretax Income | -21.15M |
| Net Income | -21.15M |
| EBITDA | -35.87M |
| EBIT | -35.95M |
| Loss Per Share | -$10.85 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 5.07M |
| Total Debt | 1.04M |
| Net Cash | 4.03M |
| Net Cash Per Share | $0.98 |
| Equity (Book Value) | 4.70M |
| Book Value Per Share | 2.41 |
| Working Capital | -6.95M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -30.59M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 84,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -30.59M |
| FCF Per Share | -$7.45 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -833.40% |
| Pretax Margin | -490.33% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -348.43% |
| Shareholder Yield | -348.43% |
| Earnings Yield | -1,808.84% |
| FCF Yield | -1,241.95% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $42.67 |
| Price Target Difference | 7,011.67% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 45.46% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 6, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -100.18 |
| Piotroski F-Score | n/a |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |